- February 2025: ~$15-18 (steady clinical progress)
- April 2025: ~$22-25 (Phase 3 data anticipation)
- June 2025: ~$35-40 (positive trial rumors)
- July 2025: $13.59 to $50+ range (explosive growth)
- August 2025: $49.96 to $55.44 (FDA catalyst surge)
How to Buy Celcuity Inc. (CELC) Shares - Investment in Celcuity Inc. (CELC) Stock
Thinking about investing in a biotech company that's making waves in cancer treatment? Celcuity Inc. (CELC) is capturing attention with its groundbreaking breast cancer therapy gedatolisib. With recent FDA breakthroughs and explosive stock performance, this could be your chance to get in on a medical revolution. We'll break down everything from current pricing to smart entry strategies.
Article navigation
- 📈 Current Stock Price and Critical Dates
- 📊 6-Month Price Journey: From Steady to Spectacular
- 🔮 Price Forecast: 2025-2030 Outlook
- ⚠️ Key Risks vs. Positive Signals
- 🛡️ What Should a Beginner Trader Do Today?
- ✅ How to Buy Celcuity Inc. (CELC) Shares – Step by Step
- 💡 Why Pocket Option Fits New CELC Investors
- 🌍 Celcuity in 2025: Oncology’s Rising Star
📈 Current Stock Price and Critical Dates
As of August 29, 2025, Celcuity Inc. (CELC) trades at $54.60 on NASDAQ. Mark your calendar: November 13, 2025 is absolutely critical—that’s when Celcuity releases its Q3 earnings. Historically, these reports have moved prices dramatically.
How FDA News Moved CELC Stock in August 2025
The recent FDA acceptance of gedatolisib’s New Drug Application created fireworks. On August 28, 2025, CELC surged 10.69% to $55.30, hitting a 52-week high of $55.44 (AInvest Report). This wasn’t just any bounce—it represented the culmination of a 210% year-to-date gain that has investors buzzing.
📊 6-Month Price Journey: From Steady to Spectacular
Celcuity’s stock has been on an absolute tear since February 2025:
The most dramatic movement occurred in late July through August, where the stock skyrocketed from approximately $13.59 to over $55—a gain of more than 300% in under six weeks. This wasn’t gradual growth; it was a vertical climb driven by clinical success and regulatory milestones.
🔮 Price Forecast: 2025-2030 Outlook
- 2025 (Year-End): $60-68
Based on current momentum and Q4 FDA submission progress, CELC could test new highs. The average analyst target sits at $53.60 (StockAnalysis), but recent upgrades suggest $66-79 targets are emerging. - 2026: $75-90
If gedatolisib receives FDA approval in 2026 as expected, commercial launch could drive significant revenue projections and stock appreciation. - 2028: $110-140
By 2028, assuming successful market penetration and potential label expansions, Celcuity could establish itself as a mid-cap biotech leader. - 2030: $160-200
Long-term success with gedatolisib and pipeline development could position Celcuity for acquisition or independent growth into a multi-billion dollar franchise.
Verdict: STRONG BUY for risk-tolerant investors. The FDA catalyst has created momentum that could continue through approval.
⚠️ Key Risks vs. Positive Signals
Risks to Consider:
- Clinical Failure Risk: Despite positive Phase 3 data, FDA could request additional studies or reject the application
- Biotech Volatility: 45.14% volatility rating means wild price swings are normal
- Regulatory Delays: FDA review process could take longer than expected
- Competition: Other PI3K inhibitors in development could challenge market share
- Funding Needs: May need to raise additional capital through stock offerings
Green Lights for 2025:
- FDA Breakthrough Status: Gedatolisib has both Breakthrough Therapy and Fast Track designations
- Phase 3 Home Run: 76% risk reduction in disease progression is exceptional data
- Market Need: HR+/HER2- breast cancer represents significant unmet medical need
- Analyst Support: Strong Buy consensus with rising price targets
- Institutional Interest: Growing Wall Street coverage and investor attention
🛡️ What Should a Beginner Trader Do Today?
- Start Small: Begin with a position size that won’t keep you up at night—biotech is volatile
- Dollar-Cost Average: Consider building your position over several weeks rather than one lump sum
- Set Alert for November 13: Q3 earnings could provide the next major catalyst
- Have an Exit Strategy: Know your profit-taking and stop-loss levels before you buy
- Humorous veteran advice: “Trading CELC is like riding a rocket—thrilling, but make sure you packed your parachute!”
✅ How to Buy Celcuity Inc. (CELC) Shares – Step by Step
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose a Trading Platform | Ensure it offers NASDAQ stocks and has reasonable fees |
| 2 | Open and Fund Your Account | Start with an amount you’re comfortable risking |
| 3 | Search for “CELC” | Use the ticker symbol, not just the company name |
| 4 | Select Order Type | Use limit orders to control your entry price |
| 5 | Review and Execute | Double-check order details before confirming |
| 6 | Set Price Alerts | Monitor for important news and price movements |
| 7 | Track Your Investment | Use portfolio tracking tools to stay informed |
| 8 | Plan Your Exit Strategy | Decide in advance when you’ll take profits or cut losses |
💡 Why Pocket Option Fits New CELC Investors
For those looking to invest in Celcuity, Pocket Option offers several advantages that make getting started easier:
- Minimum deposit of just $5—perfect for testing strategies with CELC without significant risk
- Lightning-fast verification—start trading within minutes with simple document upload
- Multiple withdrawal options—access your profits through various convenient methods
- User-friendly platform—perfect for beginners navigating biotech investments
The platform’s low barrier to entry makes it ideal for investors who want exposure to high-potential stocks like CELC without committing large amounts of capital initially.
🌍 Celcuity in 2025: Oncology’s Rising Star
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer patients. Their lead drug candidate, gedatolisib, is making history as a potent pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR pathway (Company Website).
The company’s groundbreaking Phase 3 VIKTORIA-1 trial demonstrated unprecedented results: gedatolisib-based regimens reduced disease progression risk by 76% compared to standard care, with median progression-free survival improving from 2.0 months to 9.3 months (Regulatory Filing).
Interesting Fact for 2025: Celcuity’s CEO Brian Sullivan started the company after his wife’s breast cancer diagnosis—making this not just another biotech story, but a personal mission that’s now delivering potentially life-saving medicine to patients worldwide.
FAQ
What makes Celcuity different from other biotech companies?
Celcuity's gedatolisib targets multiple pathways simultaneously (PI3K and mTOR), potentially offering superior efficacy compared to single-pathway inhibitors. The 76% risk reduction in Phase 3 trials is exceptionally strong data.
When could gedatolisib receive FDA approval?
Based on the rolling NDA submission timeline starting September 2025, potential approval could come in late 2026 if everything progresses smoothly through the RTOR program.
Is CELC too expensive after its recent run-up?
While the stock has risen significantly, analysts continue raising price targets ($66-79 range), suggesting they believe there's still upside potential despite the recent gains.
What percentage of my portfolio should I allocate to CELC?
For most investors, keeping biotech positions to 5-10% of your total portfolio is prudent due to the sector's inherent volatility and binary outcomes.
How can I stay updated on CELC news?
Follow the company's investor relations page, set up news alerts for "Celcuity" and "gedatolisib," and monitor FDA announcement calendars for regulatory updates.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.